Transcriptome analysis profile to understand mechanisms activated by FDA molecules that overcome the ATP7B mediated resistance to cisplatin in ovarian cancer IGROV-CP20 cells.
Ontology highlight
ABSTRACT: To understand whether treatments with FDA drugs Trelmisartan, Tranilast or Amphotericin B were able to downregulate pathways important to overcome resistance to cisplatin in ovarian cancer cells IGROV-0CP20 we cemployed Quant-seq Analysis.Transcriptome of the of IGROV-CP20 cells treated with cisplatin and each of the three FDA molecules were compared with untreated cells.
ORGANISM(S): Homo sapiens
PROVIDER: GSE134029 | GEO | 2020/04/13
REPOSITORIES: GEO
ACCESS DATA